Dr. Reddy's Labs.

Aug 14 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - USFDA INSPECTION AT API FACILITY IN UK CLASSIFIED 'VOLUNTARY ACTION INDICATED' AND OFFICIALLY CLOSED

Source text: ID:nBSE9nR5Rf

Further company coverage: REDY.NS

(([email protected];))

Dr. Reddy’s Laboratories’ CEO for API and Services, Deepak Sapra, resigned to pursue opportunities outside the company and was due to leave on November 12, 2026. Sapra had spent more than 23 years with the pharmaceutical maker, joining in 2003 and working across roles, responsibilities and geographies. Global generics accounted for roughly 89% of Dr. Reddy’s revenue in the June 2026 quarter, with PSAI contributing 11%. The company had consolidated revenue of about ₹33,600 crore in FY26 and net cash of ₹3,060 crore.

Powered by Tijori

Updates data on Biogen manufacturing plants in paragraph 18

Aug 11 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country.

Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly $500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors.

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one in Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

The company said in June it has invested about $1 billion in Jacksonville, Florida, to strengthen U.S.-based manufacturing for its eye care business. The new facility is expected to be fully operational in 2028, J&J said.

Roche ROG.S

The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion in U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has eight factories in the state.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Amgen said it would invest an additional $300 million in its U.S. manufacturing network, expanding its biologics facility in Puerto Rico and supporting hundreds of construction jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Bristol Myers Squibb BMY.N

The drugmaker said it would invest about $2.3 billion to build a new drug manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and about 2,000 construction-related jobs, as part of its broader $40 billion U.S. investment commitment.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K, Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

(([email protected];))

Changes dateline, adds Bristol Myers investment plan

Aug 10 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country.

Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly $500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors.

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one in Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

The company said in June it has invested about $1 billion in Jacksonville, Florida, to strengthen U.S.-based manufacturing for its eye care business. The new facility is expected to be fully operational in 2028, J&J said.

Roche ROG.S

The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion in U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Amgen said it would invest an additional $300 million in its U.S. manufacturing network, expanding its biologics facility in Puerto Rico and supporting hundreds of construction jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Bristol Myers Squibb BMY.N

The drugmaker said it would invest about $2.3 billion to build a new drug manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and about 2,000 construction-related jobs, as part of its broader $40 billion U.S. investment commitment.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K, Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

(([email protected];))

Aug 7 (Reuters) - Novartis India Ltd NOIN.BO:

• NOVARTIS INDIA - APPROVES TERMINATION OF DISTRIBUTION AGREEMENT WITH DR. REDDY’S LABORATORIES

• NOVARTIS INDIA - TERMINATION AGREEMENT WITH DR. REDDY’S EFFECTIVE SEPTEMBER 30, 2026

• NOVARTIS INDIA - TO RE-BUY EXCLUSIVITY AND MARKET ACCESS FOR PRODUCTS AFTER DRL AGREEMENT TERMINATION

Source text: ID:nBSE9P3wlf

Further company coverage: NOIN.BO

(([email protected];;))

Dr. Reddy's Laboratories received US FDA approval for its rituximab biosimilar, a biosimilar to Rituxan, for the American market. Fresenius Kabi holds exclusive rights to commercialise the product in the United States under a partnership agreement. The approval followed a recent pre-license inspection at the company's biologics manufacturing facility in Bachupally, Hyderabad, and landed on the FDA's goal date. The product was already commercialised in India, the European Union, the United Kingdom and more than 25 emerging markets, and had received marketing approval in Switzerland and Canada. Dr. Reddy's launched the rituximab biosimilar in Europe in 2025 as part of its expanding global biosimilars portfolio, which also includes bevacizumab and pegfilgrastim.

Powered by Tijori

Aug 1 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - RECEIVES U.S. FDA APPROVAL FOR RITUXIMAB BIOSIMILAR

Source text: ID:nBSE6lpY3R

Further company coverage: REDY.NS

(([email protected];))

July 29 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• USFDA COMPLETES INSPECTION AT DR. REDDY'S FTO-SEZ UNIT-02 JULY 20-29, 2026

• ISSUED FORM 483 WITH THREE OBSERVATIONS

Source text: ID:nNSE1GXc8Q

Further company coverage: REDY.NS

(([email protected];))

July 27 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S SAYS THAI FDA APPROVES NUZOLVENCE (ZOLIFLODACIN) - STATEMENT

Further company coverage: REDY.NS

(([email protected];))

Adds details paragraph 3 onwards

July 23 (Reuters) - Shares of Dr Reddy's Laboratories REDY.NS fell as much as 6.9% on Thursday after many brokerages cut their earnings forecasts for the Indian drugmaker following weaker-than-expected quarterly results and semaglutide supply disruptions.

The stock was trading 3.2% lower at 1,145 rupees as of 09:40 a.m. IST, and was the top loser on the pharma index .NIPHARM and the Nifty 50 .NSEI.

At least eight brokerages cut their target price on the company's stock as of Thursday morning, according to LSEG compiled data.

The company's weak June-quarter results have reignited concerns about profitability, with analysts warning that the pace of recovery now hinges on the successful restart of semaglutide supplies and the timely approval of biosimilar abatacept.

Dr. Reddy's, which sees semaglutide as a key growth driver in India and select overseas markets, said earlier in July its generic version would remain unavailable in India and disrupted in Canada until at least late October.

J.P. Morgan maintained its "underweight" rating and cut its target price on Dr. Reddy's stock to 1,100 rupees from 1,200 rupees, saying weak core profitability persisted despite branded business growth.

The brokerage also lowered its fiscal 2027 fiscal 2028 earnings estimates by 12% to 17% and warned that any delay in semaglutide's relaunch or abatacept approval could pose further risks.

Citi reiterated its "sell" rating and reduced its target price to 1,040 rupees, saying first-quarter margins reinforced concerns about the company's core business and prompted earnings downgrades.

Analysts expect the next leg of earnings recovery to depend on semaglutide supply resuming in November and regulatory progress for abatacept, which management expects could be approved by the end of 2026.

However, brokerages cautioned that any further delays could trigger additional earnings cuts and keep pressure on the stock.

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee)

(([email protected]; 8800437922;))

Dr. Reddy's Laboratories reported consolidated revenue of ₹80.7 billion for the quarter ended June 2026, a decline of 6% year-on-year, impacted by a sharp drop in lenalidomide sales and a ₹2.4 billion provision for out-of-specification semaglutide batches. Gross margin contracted to 46.5% from 56.9% a year earlier. In a separate development, the company disclosed that the US FDA conducted a pre-license inspection of its biologics manufacturing site in Bachupally, Hyderabad, in June, and issued a Form 483 with seven observations. The company stated it had responded within the stipulated timeline. It also named Dr. Sridevi Khambhampaty as Global Head of Biologics and appointed Deloitte Haskins & Sells as its independent registered public accounting firm for US filings.

Powered by Tijori

Dr. Reddy's Laboratories reported its Q1 FY27 results on July 22, posting a 71% year-on-year decline in profit before tax to ₹5.5 billion, weighed down by a ₹2.4 billion provision related to out-of-specification semaglutide batches. The board also approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics. Separately, the earnings release disclosed that the company's biologics facility in Bachupally, Hyderabad, received a Form 483 with seven observations from the US FDA following a pre-license inspection in June. The company stated that responses were provided within the stipulated timeline. Deloitte Haskins & Sells was also appointed as the independent registered public accounting firm for US SEC filings.

Powered by Tijori

HYDERABAD, July 22 (Reuters) - Indian drugmaker Dr Reddy's REDY.NS reported a smaller-than-expected quarterly profit on Wednesday, as muted sales of a key generic oncology drug and pricing pressure weighed on the competitive U.S. market.

Consolidated net profit tanked 68.7% to 4.44 billion rupees ($45.98 million) in the first quarter ending June 30.

Analysts, on average, had estimated profit to fall to 7.22 billion rupees, according to data compiled by LSEG.

($1 = 96.5650 Indian rupees)

(Reporting by Rishika Sadam and Kashish Tandon)

(([email protected];))

Adds details, context and background from paragraphs 2 onwards

By Nqobile Dludla

JOHANNESBURG, July 20 (Reuters) - South Africa's Aspen Pharmacare APNJ.J said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic version of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic.

Africa's biggest pharmaceutical company said in a statement that its generic semaglutide is authorized for the management of type 2 diabetes.

The expiry of Novo's patent for semaglutide, the active ingredient in the Danish drugmaker's blockbuster GLP-1 drugs Ozempic for diabetes and Wegovy for weight loss, has opened the door for several drugmakers looking to enter the Canadian market with generic versions, which are essentially copies of branded drugs.

The timing of Aspen's commercial launch in Canada remains dependent on the availability of semaglutide active pharmaceutical ingredient (API) supply from India's Dr. Reddy's Laboratories REDY.NS, the company said.

An API is the key compound in a drug that produces its therapeutic effect.

Earlier this month, Dr Reddy's said that supplies of its generic semaglutide would remain unavailable in India and face disruptions in Canada until at least late October after an impurity issue in the drug's active ingredient halted production of new batches.

In March, Aspen's CEO Stephen Saad said Aspen's generics will be manufactured at its South African and French facilities, with the bigger volumes via multi-dose pens set to be produced at the South African facility.

The French facility will produce single-dose autoinjector medicine.

(Reporting by Nqobile Dludla;
Editing by Alison Williams and Susan Fenton)

(([email protected]; +27103461066;))

July 17 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Friday that India's drug regulator has approved its obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.

Here are a few details:

• The Central Drugs Standard Control Organisation approved Wegovy's 2.4 mg semaglutide injection for the treatment of MASH, Novo Nordisk said.

• MASH is caused by a buildup of fat in the liver that can lead to inflammation and liver damage. The condition is part of a broader spectrum of fatty liver disease and can progress to more severe liver complications if left untreated.

• Novo Nordisk said about two in three people in India have fatty liver disease, highlighting the country's large potential patient population.

• It is a silent disease, and people often do not have symptoms until the disease has progressed to an advanced stage, the company added.

• Wegovy, Novo Nordisk's blockbuster obesity medicine, contains the active ingredient semaglutide and is already approved in multiple markets, including India, for chronic weight management.

• Novo has been vying for a share of India's fast-growing obesity-drug market against Eli Lilly's LLY.N Mounjaro and lower-cost generic semaglutide products launched by local drugmakers such as Dr Reddy's REDY.NS and Sun Pharma SUN.NS.

• The company sold about 76,000 units of Wegovy in India in the first six months of 2026, according to data from market researcher Pharmarack.

(Reporting by Rishika Sadam in Hyderabad; Editing by Sherry Jacob-Phillips)

(([email protected];))

Updates at close

By Kashish Tandon

July 10 (Reuters) - Dr Reddy's Laboratories REDY.NS logged its steepest weekly loss in three years on Friday, after a disruption in generic semaglutide supply raised concerns it could lose its edge in the highly competitive diabetes market.

On Thursday, the company said supplies of ‌its generic semaglutide would remain unavailable in India and face disruptions in Canada until at least late October, after an impurity issue in the drug's active ingredient halted production of new batches.

At least five brokerages cut their price targets on the Indian drugmaker's stock since the announcement, according to data compiled by LSEG, and at least three lowered earnings estimates. Analysts warned that the disruption could weaken pricing power, dent market-share gains and slow earnings growth.

Dr Reddy's stock slid as much as 3.7% before trimming losses to settle 1.8% lower at 1,246.50 rupees. It fell 9.3% on the week, making it the benchmark Nifty 50's second-worst performer.

BofA analysts said the timing of supply resumption would be critical, warning the setback could prevent Dr Reddy's from capturing high-value volumes during a limited-competition period in Canada.

Approvals in key emerging markets such as Brazil and Turkey, along with post-resumption demand trends, would be closely watched, they added.

Systematix said the disruption could erode Dr Reddy's first-mover advantage in the semaglutide segment, with competition intensifying in India, home to the world's second-largest diabetic population, as well as in overseas markets.

"I think the first-mover advantage looks like it is no more," said Shrikant Akolkar, pharma analyst at Nuvama Institutional Equities.

"I think it is a win for other companies who are left in the market. If these companies have a clear product, this temporary withdrawal by Dr Reddy's will benefit them."

The Hyderabad-based drugmaker markets semaglutide under the brand name Obeda.

Rivals Zydus Lifesciences ZYDU.NS and Sun Pharmaceutical Industries SUN.NS have also launched competing versions.

(Reporting by Kashish Tandon in Bengaluru; Editing by Abinaya V and Janane Venkatraman)

(([email protected]; 8800437922;))

July 9 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• INDIA'S DR REDDY'S EXEC: WE GOT TO KNOW ABOUT THE ISSUE ON WEDNESDAY

• DR REDDY'S EXEC: WE WILL BE ON TRACK TO SUPPLY BETWEEN 6-7 MILLION SEMAGLUTIDE PENS BETWEEN Q3 AND Q4

• DR REDDY'S EXEC: ISSUE IS NOTHING TO DO WITH WHATEVER WE SENT TO MARKET

• DR REDDY'S EXEC: ACTUAL SUPPLY TO MARKET CAN RESUME IN LATE OCTOBER TO EARLY NOVEMBER IF ISSUE RESOLVED

• DR REDDY'S EXEC: THERE WILL BE HALT OF SUPPLY BETWEEN NOW AND SEPTEMBER

• DR REDDY'S EXEC: NO QUESTION OF PRODUCT RECALL

• DR REDDY'S EXEC: THERE WAS RECALL OF ONE BATCH IN INDIA, BUT IT HAS NOTHING TO DO WITH ISSUE

• DR REDDY'S EXEC: WE MAY NEED TO WRITE DOWN SOME INVENTORY

• DR REDDY'S EXEC: IMPURITY WAS IN API AND WAS DETECTED IN FORMULATION WHEN TESTED

• DR REDDY'S EXEC: IMPURITY HAD TO DO WITH PROCESS, REACTION OF API; NO REQUIREMENT OF EQUIPMENT CHANGE

• DR REDDY'S EXEC: THIS BATCH NEVER WENT INTO MARKET, NO PRODUCT RECALL, NEVER SHIPPED TO ANY MARKET

• DR REDDY'S EXEC: NO SHORTAGE OF DEMAND, PRETTY CONFIDENT OF DEMAND

• DR REDDY'S EXEC: SHORT OF EARLIER PREDICTED TARGET, WE NOW THINK WE CAN SELL 6 TO 7 MILLION IN FISCAL 2027

• DR REDDY'S EXEC: WHEN WE GAVE EARLIER TARGET WE ASSUMED WE WOULD SELL BETWEEN JULY-SEPTEMBER, NOW UNLIKELY WE WILL DO THAT

Further company coverage: REDY.NS

(([email protected];))

Dr. Reddy's Laboratories said the USFDA completed a pre-license inspection of its biologics manufacturing facility in Bachupally, Hyderabad, on June 25, 2026. The inspection, which ran from June 16 to June 25, resulted in a Form 483 with seven observations. The company stated it will address the observations within the required timeline. The filing noted that the facility had previously undergone inspections disclosed in October 2023 and September 2025.

Powered by Tijori

By Mrinalika Roy and Sriparna Roy

June 17 (Reuters) - U.S. supplies of progesterone are coming under strain, with patients, clinicians, and pharmacists reporting recent intermittent shortages of oral versions of the hormone used in many fertility and menopause treatments.

The supply concerns come as women going through menopause across the country are already facing difficulties filling prescriptions for estrogen patches, another commonly used hormone therapy.

Demand for hormone replacement therapy, or HRT, has climbed sharply since the U.S. Food and Drug Administration removed a longstanding safety warning from many such therapies in late 2025. Doctors have also become more comfortable prescribing HRT, while women's health and menopause experts on social media platforms have encouraged its use.

That has combined to produce tight supplies of progesterone, often prescribed to reduce the risk of uterine cancer, alongside estrogen for relief of menopause symptoms such as hot flashes, mood changes and osteoporosis.

Robin Wilson, 64, director of operations for the Iowa State wrestling program, said progesterone capsules became more difficult to get about a year ago after nearly nine years without supply issues.

Her local pharmacy in Ames, Iowa, recently could not fill her usual 90-day prescription, offering instead a smaller supply while awaiting a shipment. "This is the first time this has happened," Wilson said.

SUPPLIES TIGHTEN WITH DEMAND SURGE

Progesterone-containing HRT prescriptions for women aged 45 and older have more than tripled since January 2021, to about 12 women per 1,000 in May of 2026, according to health analytics company Truveta, whose electronic health record database covers more than 130 million patients in all 50 states.

Prescribing rates have increased more than 19% since the FDA's label change, the data showed.

"While estrogen patches are incurring the biggest supply challenges, progesterone supplies are beginning to be stretched too," said Dr. Kathleen Jordan, chief medical officer of telehealth provider Midi Health.

The American Society of Health-System Pharmacists lists certain oral progesterone capsule products from Amneal Pharmaceuticals AMRX.O and Hikma Pharmaceuticals HIK.L in its shortages database.

"We have seen increased demand for progesterone capsules in recent months," said Amneal, adding that it is increasing manufacturing capacity at its New York facility and continues to meet contracted supply commitments.

Hikma did not respond to requests for comment.

A spokesperson for CVS Health CVS.N, one of the nation's largest pharmacy chains, said manufacturers have been unable to provide sufficient HRT supplies for several months.

According to an FDA database, nine companies manufacture oral progesterone, including Teva TEVA.TA and Dr. Reddy's REDY.NS. Teva did not respond to a request for comment, while Dr. Reddy's said the product has not been part of its U.S. portfolio since 2022 and the company does not manufacture or market it.

The FDA does not list progesterone as being in shortage.

A spokesperson for the U.S. Department of Health and Human Services, which oversees the FDA, said one manufacturer is experiencing delays but others have product available. The agency is working with manufacturers to help ensure supplies meet demand, the spokesperson said.

COMPOUNDING CAUTION

Clinicians say progesterone shortages have been milder than those affecting estrogen patches, though some patients still face delays getting prescriptions filled.

This is partly because women who have had a hysterectomy do not need progesterone with HRT, and because alternatives like combination patches, progestin-releasing IUDs, and oral progestins reduce reliance on any single formulation.

Manufacturers have not disclosed a specific cause for shortages, said Michael Ganio, senior director of pharmacy practice and quality at ASHP, the pharmacists' trade group.

"Without a reason, it can be difficult to know whether there is disruption due to manufacturing or other delays, or an increase in demand that the available market supply cannot meet," Ganio said.

Some have turned to compounding pharmacies for progesterone and estrogen, said Valerie Richards, director of clinical services at Strive Compounding Pharmacy.

"Providers are not waiting for the commercial supply chain to sort itself out," she said.

Compounding pharmacies do their own preparation of pharmaceutical ingredients, which is allowed when the FDA has declared a drug in shortage or for personalized doses not otherwise available.

Dr. Gillian Goddard, adjunct assistant professor of medicine at the NYU Grossman School of Medicine, said compounded products not subject to the strict regulatory process of FDA-approved drugs "could contain too much or too little progesterone," leading to health issues and potentially costly ultrasounds and biopsies.

"I always caution against using compounded products," she said.

(Reporting by Mrinalika Roy and Sriparna Roy in Bengaluru; Editing by Caroline Humer and Bill Berkrot)

(([email protected];))

Recasts paragraph 1, 2; updates headline

June 15 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country.

Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly $500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors.

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

The company said in June it has invested about $1 billion in Jacksonville, Florida, to strengthen U.S.-based manufacturing for its eye care business. The new facility is expected to be fully operational in 2028, J&J said.

Roche ROG.S

The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Amgen said it would invest an additional $300 million in its U.S. manufacturing network, expanding its biologics facility in Puerto Rico and support hundreds of construction jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K, Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

(([email protected];))

June 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - ANNOUNCES THE FIRST-TO-MARKET LAUNCH OF BOSUTINIB TABLETS 400MG IN THE UNITED STATES

Source text: ID:nPLXQ94HLR

Further company coverage: REDY.NS

(([email protected];))

An alert on the New York Stock Exchange providing a daily premarket update, tagged to Asana Inc ASAN.N, Dell Technologies DELL.N, Dr Reddy's REDY.NS, IDT Corp IDT.N, and Intercontinental Exchange ICE.N, was inadvertently published and has been withdrawn.

There will be no substitute.

STORY_NUMBER: nTUA9GZNFQ

STORY_DATE: 29/05/2026

STORY_TIME: 12:55 PM GMT

(([email protected]))